A PHASE 1, OPEN-LABEL MULTI-CENTER FIRST IN HUMAN STUDY OF THE SAFETY, TOLERABILLITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF TPX-0022 A NOVEL MET/CSF1R/SRC INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING GENETIC ALTERATIONS IN MET
2019-002459-40TUMORES SOLIDOS AVANZADOSFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR
